Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Deferred Tax Liability: 2022-2025

Historic Non-Current Deferred Tax Liability for InMed Pharmaceuticals (INM) over the last 3 years, with Jun 2025 value amounting to $20,000.

  • InMed Pharmaceuticals' Non-Current Deferred Tax Liability was N/A to $20,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $20,000, marking a year-over-year change of. This contributed to the annual value of $20,000 for FY2025, which is N/A change from last year.
  • InMed Pharmaceuticals' Non-Current Deferred Tax Liability amounted to $20,000 in FY2025, which was down 90.53% from $211,266 recorded in FY2023.
  • InMed Pharmaceuticals' 5-year Non-Current Deferred Tax Liability high stood at $211,266 for FY2023, and its period low was $20,000 during FY2025.
  • Moreover, its 2-year median value for Non-Current Deferred Tax Liability was $115,633 (2023), whereas its average is $115,633.
  • Data for InMed Pharmaceuticals' Non-Current Deferred Tax Liability shows a peak YoY skyrocketed of 194.22% (in 2023) over the last 5 years.
  • InMed Pharmaceuticals' Non-Current Deferred Tax Liability (Yearly) stood at $71,806 in 2022, then soared by 194.22% to $211,266 in 2023, then reached $20,000 in 2025.